A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.
LACTAMS forming compounds with a ring size of approximately 1-3 dozen atoms.
Benzene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
Hydrocarbon rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.
The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. CD44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.
A species in the genus RHADINOVIRUS, subfamily GAMMAHERPESVIRINAE, isolated from patients with AIDS-related and "classical" Kaposi sarcoma.
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
The thin serous membrane enveloping the lungs (LUNG) and lining the THORACIC CAVITY. Pleura consist of two layers, the inner visceral pleura lying next to the pulmonary parenchyma and the outer parietal pleura. Between the two layers is the PLEURAL CAVITY which contains a thin film of liquid.
A general term for various neoplastic diseases of the lymphoid tissue.
Fluid accumulation within the PERICARDIUM. Serous effusions are associated with pericardial diseases. Hemopericardium is associated with trauma. Lipid-containing effusion (chylopericardium) results from leakage of THORACIC DUCT. Severe cases can lead to CARDIAC TAMPONADE.

Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. (1/945)

Signaling through A2A adenosine receptors (A2AR) regulates T lymphocyte expansion and modulates T cell receptor (TCR)-mediated effector functions in vitro. To understand the role of A2ARs in the regulation of immune response, we investigated the expression levels of this receptor in different functional lymphocyte subsets. Monoclonal anti-A2AR antibody was used to develop a flow cytometric assay to quantify the expression A2ARs on lymphocytes. We report that detectable levels of expression of A2ARs are much higher among T cells than B cells. More CD4(+) than CD8(+) T cells express A2ARs, but activation of T cells increases A2AR expression, predominantly in CD8(+) T cells. No significant differences were found in the proportion of A2AR+ cells between CD8(low) and CD8(high) T cells or between TCR/CD3(low) and TCR/CD3(high) T cells. Studies of T helper cell subsets (TH1 and TH2) reveal that lymphokine-producing cells are much more likely to express A2ARs than are cells that do not produce lymphokines. These results suggest that A2ARs are variably expressed on T cell subsets and may regulate cytokine production in activated T lymphocytes.  (+info)

Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). (2/945)

PURPOSE: The diagnosis of Buerger's disease has depended on clinical symptoms and angiographic findings, whereas pathologic findings are considered to be of secondary importance. Arteries from patients with Buerger's tissue were analyzed histologically, including immunophenotyping of the infiltrating cells, to elucidate the nature of Buerger's disease as a vasculitis. METHODS: Thirty-three specimens from nine patients, in whom Buerger's disease was diagnosed on the basis of our clinical and angiographic criteria between 1980 and 1995 at Nagoya University Hospital, were studied. Immunohistochemical studies were performed on paraffin-embedded tissue with a labeled streptoavidin-biotin method. RESULTS: The general architecture of vessel walls was well preserved regardless of the stage of disease, and cell infiltration was observed mainly in the thrombus and the intima. Among infiltrating cells, CD3(+) T cells greatly outnumbered CD20(+) B cells. CD68(+) macrophages or S-100(+) dendritic cells were detected, especially in the intima during acute and subacute stages. All cases except one showed infiltration by the human leukocyte antigen-D region (HLA-DR) antigen-bearing macrophages and dendritic cells in the intima. Immunoglobulins G, A, and M (IgG, IgA, IgM) and complement factors 3d and 4c (C3d, C4c) were deposited along the internal elastic lamina. CONCLUSION: Buerger's disease is strictly an endarteritis that is introduced by T-cell mediated cellular immunity and by B-cell mediated humoral immunity associated with activation of macrophages or dendritic cells in the intima.  (+info)

Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. (3/945)

Plasma cells are found surrounding the inflammatory infiltrates of macrophages, T, and B cells in the synovial tissue of patients with rheumatoid and reactive arthritis. This characteristic arrangement suggests that in the synovial tissue CD20+ B cells differentiate into plasma cells. To examine clonal relationships, we have used micromanipulation to separately isolate CD20+ B cells and plasma cells from single infiltrates. DNA was extracted, and from both populations the VH/VL gene repertoires was determined. The data show that in the inflamed synovial tissue activated B cells are clonally expanded. During proliferation in the network of follicular dendritic cells, V gene variants are generated by the hypermutation mechanism. Surprisingly, we do not find identical rearrangements between CD20+ B cells and plasma cells. Nevertheless, the finding of clonally related plasma cells within single infiltrates suggests that these cells underwent terminal differentiation in the synovial tissue. These results indicate that B cell differentiation in the synovial tissue is a dynamic process. Whereas CD20+ B cells may turnover rapidly, plasma cells may well be long lived and thus accumulate in the synovial tissue. The analysis of individual B cells recovered from synovial tissue opens a new way to determine the specificity of those cells that take part in the local immune reaction. This will provide new insights into the pathogenesis of chronic inflammatory diseases like rheumatoid or reactive arthritis.  (+info)

Histopathologic features and expression of Bcl-2 and p53 proteins in primary gastric lymphomas. (4/945)

The aim of this study is to present a histopathologic and immunohistochemical analysis of primary gastric lymphomas which were reclassified according to the concept of mucosa associated lymphoid tissue (MALT). The resected specimens from 41 patients with primary gastric lymphoma were investigated retrospectively. Immunohistochemical study was done to analyze the immunophenotype and bcl-2 and p53 proteins expression. Twenty three of the cases had tumors mainly located in the antrum. Histologically, 12 were low grade and 20 were high grade B-cell lymphoma of MALT, 9 other B-cell nonHodgkin's lymphomas. Helicobacter pylori was identified in 72% of the cases. According to Musshoff's modification, most of the MALT lymphoma cases had stage I or II disease. There was significant difference between low and high grade cases, in respect to depth of invasion in gastric wall. Immunohistochemically, the neoplastic cells in all MALT lymphomas expressed B-cell phenotype. Bcl-2 protein was found to be expressed in 59% and p53 protein expression was detected in 72% of cases. Among the B-cell lymphoma of MALT, bcl-2 positivity decreased and p53 positivity increased significantly as the histological grade advanced. So, an inverse correlation was observed between the expression of bcl-2 and p53. In conclusion, most primary gastric lymphomas are low or high grade B-cell MALT lymphomas and appear to arise in MALT acquired as a reaction to Helicobacter pylori infection. Expression of bcl-2 and p53 in gastric lymphomas may be associated with transformation from low-grade to high-grade disease.  (+info)

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. (5/945)

Rituximab is a chimeric antibody with human gamma-1 and kappa constant regions and murine variable regions. It recognizes the CD20 antigen, a pan B-cell marker. Therapeutic trials in patients with B-cell non-Hodgkin's lymphoma (NHL) have shown significant efficacy with a primary response rate of 50%, and a secondary response rate of 44% after repeat treatments in prior responders. The selection for proliferating tumor cells that no longer express CD20 may compromise repeated treatment. We have identified a patient who developed a transformed NHL that lost CD20 protein expression after two courses of therapy with rituximab. In a pretreatment lymph node biopsy, 83% of B cells (as defined by CD19 and surface immunoglobulin) expressed surface CD20. A biopsy from the recurrent tumor after two courses of rituximab revealed a diffuse large cell NHL where 0% of B cells expressed CD20 with no evidence of bound rituximab. Cytoplasmic staining showed no CD20 protein. Sequencing of immunoglobulin heavy chain cDNA identified identical variable sequences in the initial and recurrent lymphomas, confirming the association between the two tumors. Literature and database review suggests that approximately 98% of diffuse large cell lymphomas express CD20, which suggests that these tumors rarely survive without CD20. This is the first identified case of loss of CD20 expression in a lymphoma that has relapsed after rituximab therapy, although several other cases have since been identified. Considering the significant number of patients treated with anti-CD20 antibodies, this may occur only rarely and is unlikely to preclude recurrent therapy with anti-CD20 antibodies in the majority of patients. However, because many patients have relapsed after anti-CD20 antibody therapy and have not been biopsied to identify clones with down-regulated CD20 antigen, we do not currently know the true frequency of this phenomenon. When possible, patients should undergo evaluation for CD20 expression before repeated courses of anti-CD20 therapy.  (+info)

Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. (6/945)

T-cell-rich B-cell lymphoma (TCRBCL) belongs to the group of diffuse large cell lymphomas (DLL). It is characterized by a small number of tumor B cells among a major population of nonmalignant polyclonal T cells. To identify the developmental stage of the tumor progenitor cells, we micromanipulated the putative neoplastic large CD20(+) cells from TCRBCLs and amplified and sequenced immunoglobulin (Ig) V gene rearrangements from individual cells. In six cases, clonal Ig heavy, as well as light chain, gene rearrangements were amplified from the isolated B cells. All six cases harbored somatically mutated V gene rearrangements with an average mutation frequency of 15.5% for heavy (VH) and 5.9% for light (VL) chains and intraclonal diversity based on somatic mutation. These findings identify germinal center (GC) B cells as the precursors of the transformed B cells in TCRBCL. The study also exemplifies various means how Ig gene rearrangements can be modified by GC B cells or their malignant counterparts in TCRBCL: In one case, the tumor precursor may have switched from kappa to lambda light chain expression after acquiring a crippling mutation within the initially functional kappa light chain gene. In another case, the tumor cells harbor two in-frame VH gene rearrangements, one of which was rendered nonfunctional by somatic mutation. Either the tumor cell precursor entered the GC with two potentially functional in-frame rearrangements or the second VHDHJH rearrangement occurred in the GC after the initial in-frame rearrangement was inactivated by somatic mutation. Finally, in each of the six cases, at least one cell contained two (or more) copies of a clonal Ig gene rearrangement with sequence variations between these copies. The presence of sequence variants for V region genes within single B cells has so far not been observed in any other normal or transformed B lymphocyte. Fluorescence in situ hybridization (FISH) points to a generalized polyploidy of the tumor cells.  (+info)

Distribution of lymphocytes and adhesion molecules in human cervix and vagina. (7/945)

Knowledge of the histological distribution of leucocytes and adhesion molecules in the human genital tract is scarce although local immunity in this region is important. Using immunohistochemical methods, we here describe the organization of CD3+, CD8+ and CD4+ T cells, CD19+ B cells, CD38+ plasma cells, major histocompatibility complex (MHC) class II+ antigen-presenting cells and CD14+ monocytes, as well as the expression of endothelial addressins in normal human ecto-cervical and vaginal mucosa. T cells were clustered in a distinct band beneath the epithelium and were also dispersed in the epithelium and the lamina propria, whereas CD38+ plasma cells were present only in the lamina propria. MHC class II+ cells were numerous in the lamina propria and in the epithelium, where they morphologically resembled dendritic cells. Lymphoid aggregates containing CD19+ and CD20+ B cells as well as CD3+, CD4+ and CD8+ cells were also found in the cervix. The mucosal addressin cell adhesion molecule-1 (MAdCAM-1) was not expressed on the vascular endothelium in the cervical or vaginal mucosa. In contrast, intercellular adhesion molecule-1 (ICAM-1), vascular adhesion protein-1 (VAP-1) and P-selectin were expressed in all tissue samples, and vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were found in four of seven samples. We conclude that the distribution of leucocytes and adhesion molecules is very similar in the ecto-cervical and the vaginal mucosa and that the regulation of lymphocyte homing to the genital tract is different from that seen in the intestine. Our results also clearly suggest that the leucocytes are not randomly scattered in the tissue but organized in a distinct pattern.  (+info)

Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. (8/945)

The heavy (VH) and light (VL) chain variable regions of the murine anti-human CD20 mAb 1F5 were cloned, and four single-chain Ab (scFv) molecules were constructed using linker peptides of variable lengths to join the VH and VL domains. Three constructs were engineered using linker peptides of 15, 10, and 5 aa residues consisting of (GGGGS)3, (GGGGS)2, and (GGGGS)1 sequences, respectively, whereas the fourth was prepared by joining the VH and VL domains directly. Each construct was fused to a derivative of human IgG1 (hinge plus CH2 plus CH3) to facilitate purification using staphylococcal protein A. The aggregation and CD20 binding properties of these four 1F5 scFv-Ig derivatives produced were investigated. Both size-exclusion HPLC column analysis and Western blots of proteins subjected to nonreducing SDS-PAGE suggested that all four 1F5 scFv-Ig were monomeric with m.w. of approximately 55 kDa. The CD20 binding properties of the four 1F5 scFv-Ig were studied by ELISA and flow cytometry. The 1F5 scFv-Ig with the 5-aa linker (GS1) demonstrated significantly superior binding to CD20-expressing target cells, compared with the other scFv-Ig constructs. Scatchard analysis of the radiolabeled monovalent GS1 scFv-Ig revealed a binding avidity of 1.35 x 108 M-1 compared with an avidity of 7.56 x 108 M-1 for the native bivalent 1F5 Ab. These findings suggest that the GS1 scFv-Ig with a short linker peptide of approximately 5 aa is the best of the engineered constructs for future studies.  (+info)

The first study of veltuzumab given IV weekly in NHL patients (IM-T-hA20-01) has shown excellent tolerability and even efficacy at weekly intravenous doses as low as 80-120 mg/m2 over 4 consecutive weeks. These clinical results confirm experiments laboratory studies. Laboratory studies using Veltuzumab administered subcutaneously showed potent activity based on B-cell depletion. The current studys goal is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in patients with NHL or ...
Find everything you need to know about Ofatumumab (Arzerra), including what it is used for, warnings, reviews, side effects, and interactions. Learn more about Ofatumumab (Arzerra) at EverydayHealth.com.
通用名】 ARZERRA 【英文名】ARZERRA(ofatumumab)Injection 【中文名】奥法木单抗ARZERRA 【生产厂家】 葛兰素史克公司 【规 格 .... ...
The treatment regimen consists of 2 elements. The first element is represented by one courses of veltuzumab (4 weekly injections of 200 mg/m2). 90Y-epratuzumab will be given as 2 injections at escalating doses 1 week apart and administered starting one week following the 4th veltuzumab injection.. After confirming eligibility and undergoing baseline assessments, the treatment starts with an imaging study using 111In-epratuzumab (5-mCi 111In-DOTA-epratuzumab co-infused with a total of 1.5 mg/kg unlabeled epratuzumab). Blood samples (~7 samples, 5 mL each) for pharmacokinetic analysis will be collected over 5-7 days, and patients will be imaged on 4 separate occasions (e.g., the day of injection (Day 0), Day 1, Day 3, 4, or 5, and day 6 or 7).. The patient will then initiate veltuzumab treatments starting 7 days after the 111In-epratuzumab injection. Veltuzumab is given in 4 weekly doses, each 200 mg/m2. A single blood sample will be taken before each veltuzumab dose to assess residual veltuzumab ...
TY - JOUR. T1 - The epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodies. AU - Li, Jia Ling. AU - Shen, Guo Liang. AU - Ghetie, Maria Ana. AU - May, Richard D.. AU - Till, Mark. AU - Ghetie, Victor. AU - Uhr, Jonathan W.. AU - Janossy, George. AU - Thorpe, Philip E.. AU - Amlot, Peter. AU - Vitetta, Ellen S.. PY - 1989/1. Y1 - 1989/1. N2 - The CD22 antigen is expressed on the surface of normal human B cells and some neoplastic B cell lines and tumors. Previous cross-blocking studies using a panel of monoclonal anti-CD22 antibodies have defined four epitope groups, termed A-D. In the present studies, we have further dissected the epitopes recognized by four monoclonal anti-CD22 antibodies using immunopre-cipitation and cross-blocking techniques, immunofluorescence analyses with a variety of cell lines, and immunoperoxidase analyses of 36 normal human tissues. Two of the antibodies, HD6 and RFB4, have been described previously, and two, UV22-1 and UV22-2, are ...
I think the new pms-rituxan studies are exploring the possibility that the treatment failed because IV administration barely penetrates the cns. The assumption is that it works in rrms because the bbb is open and therefore the rituxan can get into the cns. I believe this logic is also part of the suitability criteria for hsct protocols...no relapses, no joy or something like that. The new studies all have an IT component. There is conflicting information out there regarding the usefulness of rituxan in the cns. Some claim the cns B cells arent cleared out by IT rituxan. Others claim they do. Based on successful use of IT rituxan for CNS lymphomas that were NOT managed by IV rituxan, I think the cns B cells are cleaned up by IT rituxan. Im not a doctor though...just a rampant speculator ...
Thank you for your interest in spreading the word about Haematologica.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Fingerprint Dive into the research topics of Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohns disease. Together they form a unique fingerprint. ...
Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with...
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles).
Ofatumumab is a human monoclonal antibody for the CD20 protein. Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature B-lymphocyte) and on B-cell CLL. The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates immune effector functions to result in B-cell lysis in vitro. Ofatumumab received FDA approval on April 17, 2014, for use in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate. Ofatumumab was also approved by Health Canada on August 13th, 2012.
After three months of Chemo, the Fludarabine/Mitoxantrone is really kicking his bone marrow but its not doing a whole lot to the cancerous lymphocytes, so the new plan is to add Rituxan. Rituxan is a monoclonal antibody which specifically targets mature B Lymphocytes (as opposed to ordinary chemo which kills a lot of innocent bystander cells.) This is good news, in my opinion - I was hoping they would try Rituxan soon. But of course, Rituxan has its own sticky wickets, and the first one comes up tomorrow when Dave gets his first dose of Rituxan ...
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr infusion of immunotoxin in a Phase I study to determine dose li
My immune system has been depleted to super low levels by years of Rituxan and other medications and yet, I am still having a WG flare and need to get on a primary immune suppressant. Methotrexate and prednisone alone is not getting the job done. My doctor has ordered a Rituxan infusion. Im wondering what would be the smallest dose that might be effective. What have other people done? If you have been on a smaller than normal dose I would like to hear about your experience. Perhaps
Linfomas são doenças originárias do sistema linfático, descritos por Thomas Hodgkin em 1932. São tradicionalmente classificados em dois grupos básicos: doenças de Hodgkin e linfomas do tipo não hodgkin...
Efficacy and safety information from the PePRS Trial, which studied RITUXAN® (rituximab) induction and follow-up treatment of pediatric patients with GPA and MPA. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
RITUXAN® (rituximab) patient resources including FAQs, infusion center locators and downloadable forms to help support your patients on their GPA & MPA treatment journey. Please see Important Safety Information including Boxed Warning and Full Prescribing Information for more information.
Monoclonal antibody therapy targeted therapy that can be used to treat colon cancer and other cancers. Find out about how it works and side effects.
The main purpose of this study is to examine how two separate groups of 17p deletion Chronic lymphocytic leukemia (CLL) participants respond to sequenti
The goal of this clinical research study is to learn if ofatumumab can help to control CLL/SLL that has not yet been treated. The safety of this drug will also be studied.
This month I had my first two infusions of Rituxan to treat my RRMS and I am wondering how long before I feel better? Should it be immediate - once the B cells are targeted/depleted? Or is there a delay ...
I know the side effects to look for while infusing Rituxan. My question is how does it effect the red count (H&H) after the infusion? Does it lower it as much as some other chemotherapy drugs or
Has anyone tried Rituxan (form of chemo) for there RA? I had one infusion then had to stop because i have a blocked artery and can resume taking it after i have...
Mouse Monoclonal Anti-CD45RB Antibody (BRA-11 (same as BRA-11G)) [DyLight 488]. B-Cell Marker. Validated: WB, ELISA, Flow, ICC/IF, IHC-Fr, IHC-P. Tested Reactivity: Human, Monkey (Negative). 100% Guaranteed.
Mouse Monoclonal Anti-CD83 Antibody (HB15e) [Unconjugated]. Validated: Flow, CyTOF-ready, ICC. Tested Reactivity: Human. 100% Guaranteed.
Rituximab Coupon- Get your Free Rituximab coupon & Discount Drug Card. Access thousands of free medicine coupons for instant savings.
maybe its important to test and treat active infections before one starts rituximab and knocks out part of the immune system. active infections would...
Ռիտուքսիմաբը հայտնաբերվել է գիտնական Նաբիլ Հաննայի և նրա աշխատակիցների կողմից IDEC դեղագործական կազմակերպությունում IDEC-C2B8 անվան տակ։ Դեղի արտոնագիրը տրամադրվել է 1998-ին և վերջացել 2015թ-ին[39]։ Կլինիկական հետազոտություններում իր արդյունավետության և անվտանգության շնորհիվ[40], ռիտուքսիմաբը 1997թ-ին հաստատվեց սննդի և դեղերի վերահսկման կազմակերպության կողմից B բջջային ոչ-Հոջկինյան լիմֆոմաների՝ այլ քիմիոթերապիաների նկատմամբ կայուն ձևերի բուժման համար[41]։ Ռիտուքսիմաբը CHOP սխեմայի հետ միասին ավելի արդյունավետ է, քան CHOP սխեման առանձին տարածուն մեծ B բջջային ...
Read more about the safety and tolerability profile of KESIMPTA and learn about possible adverse reactions. See full prescribing and safety information.
Rituximab (RTX) may favorably affect skin and lung fibrosis in patients with systemic sclerosis (SSc); however, the underlying molecular mechanisms remain unknown. We aimed to explore the hypothesis that RTX may mediate its antifibrotic effects by regulating the expression of Dickkopf-1 (Dkk-1), an inhibitor of the Wnt pathway. Fourteen patients with SSc and five healthy subjects were recruited. Dkk-1 expression was immunohistochemically assessed in skin biopsies obtained from 11 patients with SSc (8 treated with RTX and 3 with standard treatment), whereas DKK1 gene expression was assessed in 3 patients prior to and following RTX administration. In baseline biopsies obtained from all patients with SSc but not in healthy subjects, Dkk-1 was undetectable in skin fibroblasts. Following RTX treatment, four out of eight patients had obvious upregulation of Dkk-1 skin expression. Similarly, RTX treatment correlated with a significant 4.8-fold upregulation of DKK1 gene expression (p = 0.030). In contrast,
This open-label, randomized study will compare the efficacy of GDC-0199 plus rituximab (GDC-0199+R) with bendamustine plus MabThera/Rituxan (Rituximab) (B+R) in patients with relapsed or resistant chronic lymphocytic leukemia. Patients will be randomized 1:1 into the two arms. Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2).. Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day 1 and bendamustine infusions (70 mg/m2) on Days 1 and 2 of each 28-day cycle.. Patients in the GDC-0199+R arm will continue GDC-0199 treatment until disease progression or 2 years since treatment start, whichever comes first. Anticipated time on study is up to 5 years.. ...
Paediatric onset multiple sclerosis (POMS) is characterized by high inflammatory activity. No disease modifying treatment has been approved for POMS. The objective of this report was to report the use of rituximab, a B cell depleting monoclonal anti-CD20-antibody, in POMS. This is a retrospective case series at four specialized MS centres in Sweden. Participants were identified through the Swedish MS-registry and our own patient stocks. Data were collected through medical charts review. We identified 14 POMS patients treated with i.v. rituximab 500-1000 mg every 6th to 12th months. Median age at disease onset was 14.7 years, median age at rituximab treatment initiation was 16.5 years, and median treatment duration was 23.6 months. No relapses were reported, and the EDSS scores remained stable or decreased in 13 of 14 cases during rituximab treatment. Beyond 6 months from initiating rituximab treatment, only one new lesion was detected on MRI. No serious AEs were reported. The drug survival was ...
WALTHAM, Mass., Nov. 6 /PRNewswire/ -- Decision Resources, one of the worlds leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists anticipate using Bristol-Myers Squibbs Orencia and Biogen Idec/Genentech/ Chugai/Zenyaku Kogyos Rituxan, also marketed as Roches MabThera, more frequently in first- and second-line biologic therapy through 2010 for the treatment of rheumatoid arthritis. Currently, surveyed rheumatologists prescribe Orencia in earlier lines of therapy than Rituxan - 78 percent of them most commonly prescribe Orencia as a third-line biologic, whereas 51 percent of them use Rituxan as a fourth-line biologic, stated Madhuri Borde, Ph.D., analyst at Decision Resources. Surveyed rheumatologists contend that physician familiarity, concern about the long-term effects of B-cell depletion with Rituxan and preference for Orencias mechanism of action influences physicians to prescribe Orencia instead of ...
The depletion of CD19+ B cells by CD19-targeted CAR CD8+ T cells effectively eliminated autoantibody production and deferred or reversed disease manifestations of experimental lupus in two mouse models. These results contrast with previous results in the same mouse models, which showed resistance to anti-CD20 antibody-mediated B cell depletion (11-13). We propose that CD19-targeted CAR T cells have superior efficacy because cytotoxic T cells induce target cell death by a direct mechanism, whereas antibody-mediated cytotoxicity requires the buildup of bound antibody for complement-dependent target cell lysis, antibody-dependent cellular cytotoxicity, or clearance by phagocytes. Previous studies indicated that in models of lupus, the increased abundance of endogenous antibodies and immune complexes impairs B cell depletion by macrophages (12). Thus, anti-CD20 antibody was only effective if given repeatedly and at high doses to autoimmune mice. CD19-targeted CAR T cells, in contrast, kill B cells ...
Conclusions: Ofatumumab (up to 700 mg) given 2 weeks apart was not associated with any unexpected safety concerns and was well tolerated in patients with RRMS. MRI data suggest a clinically meaningful effect of ofatumumab for all doses studied. Results warrant further exploration of ofatumumab in RRMS. Classification of evidence: This study provides Class II evidence that in patients with RRMS, ofatumumab compared with placebo does not increase the number of serious adverse events and decreases the number of new MRI lesions. (Source: Neurology)
Hi Everyone. What an interesting topic - Ill throw in what I know for now if thats ok?. In the UK were told generally that Rituxan / Rituximab has no side effects except for during the actual infusion process. These effects include flushing, closing of the throat or tight chest sensations, chills, palps and feelings of fever. Also BP can go up or down.. Generally if they slow down the infusion these problems go away. My infusion used to take 6 to 8 hours each time! (everyone else was about 1 - 2 hours). Were told that there should be no after effects other than maybe an elevated Uric Acid level as the Rituxan kills off the bad cells and the body trys to flush them out - were usually given an Anti-Gout medication here (allopurinol) to counter act those effects.. Its interesting that you all speak of a rash and itching sensation as I had that really badly twice in the last year BUT have been off Rituxan for over 2 years! My GP said it was an allergic reaction to something and since a new ...
Monoclonal human IgG1 antibody against human CD20 Anti-hCD20-hIgG1 features the constant region of the human IgG1 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphoc
Three patients enrolled in this study had non-follicular lymphoma histologies. One with small lymphocytic lymphoma achieved a complete response, currently ongoing now 72 weeks after treatment. The other 2 patients (one SLL, one MZL) entered with high levels of circulating B cells and failed to achieve an objective response. We have reported that in patients with chronic lymphocytic leukemia (CLL), the same subcutaneous doses and dosing schedule of veltuzumab used here also failed to achieve meaningful clinical benefit, but had evidence of pharmacological activity with transient decreases in the high levels of circulating leukemic B cells.32 For subcutaneous injections, more frequent or extended dosing or combination therapy with other agents will likely be required to overcome the higher antigen burden in these settings, consistent with the experience of other anti-CD20 antibodies which are given intravenously at much higher doses for patients with chronic lymphocytic leukemia.21. Compared to ...
The decline in the numbers of inflammatory cells and adhesion molecules in synovial tissue after CD4+ cell depletion supports the view that CD4+ T cells orchestrate local cellular infiltration. The lack of clinical effect of anti-CD4 therapy might be explained by an insufficient decrease in the numb …
Significant peripheral blood CD4+ T-cell depletion has been observed after a first cycle of rituximab, a monoclonal antibody directed against the CD20 antigen, which is currently used in rheumatoid arthritis. Of note, an absence of CD4+ T-cell decrease has been observed in non-responders. Herein, we describe CD4+ T-cell changes over repeated cycles of rituximab and their relationship with clinical outcomes.. METHODS ...
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced today the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Arzerra™(ofatumumab) to treat patients whose chronic lymphocytic leukaemia (CLL) is resistant (refractory) to previous therapies. If approved, ofatumumab would be the first anti-CD20 monoclonal antibody available for this patient population.
Background: The PRIMA study showed that 2 years of R-M therapy after immunochemotherapy as first line treatment of follicular lymphoma reduced the risk of disease progression compared to OBS (Salles et al, Lancet 2011). Per-protocol analyses showed that R-M did not adversely affect patient-reported quality of life.
Monoclonal antibody therapy is a type of treatment for cancer that is given in medicines to attack certain parts of cancer cells. Learn more about how this treatment works.
This study investigated the efficacy and tolerability of rituximab for the treatment of active rheumatoid arthritis in patients with incomplete B cell depletion
Summary Phase III Pivotal Study of Ofatumumab in Refractory CLL Meets Primary Endpoint Genmab A S (OMX GEN) and GlaxoSmithKline announced today positive top-lin
Chronic Lymphocytic Leukemia (CLL) - updated results of a phase III trial finds that idelalisib combined with ofatumumab is safe and effective in relapsed patients
1 Answer - Posted in: rituxan, skin, infusion - Answer: I develop raised hives, used lotion, ice, 2 Benadryl, hydrocortisone cream.
Clinicians developed a model for distributing COVID-19 neutralizing monoclonal antibody treatments that they said may be useful for other large health systems.In an article published in Open Forum Infectious Diseases, they examined the allocation and administration of antibody treatments in 35 hospitals and several senior community facilities, skilled nursing facilities and outpatient providers
This phase II trial studies how well acalabrutinib, lenalidomide, and rituximab work in treating patients with CD20 positive stage III-IV, grade 1-3a...
Rituximab Helps in Sjgrens Syndrome By Nancy Walsh, Contributing Writer, MedPage Today Published: April 06, 2010 Reviewed by Dori F. Zaleznik, MD;...
OK.. I read this last night and had to post about it. Two Norwegian Drs have made a major breakthrough in CFS. They have discovered that a drug (Rituximab) used to treat certain cancers, significantly helped 2 out of 3 cases of CFS, and even completely cured some. While it may not be the answer…
Painted by Valentina Ramos, Butterflies Ramos wall mural from Murals Your Way will add a distinctive touch to any room. Choose a pre-set size, or customize to your wall.
Dr. Lindsay N. Shroyer Near Me at Ramos Center. Meet Dr. Lindsay N. Shroyer and Find Out How Her Expertise Can Help You Manage Your Pain.
引用Abcams Anti-CD45R抗体[RA3-6B2] (ab64100)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
引用Abcams Anti-CD14抗体(ab45870)的参考文献列表。为您列举引用本产品的发表文章,并提供信息包括论文文献数据库中的检索编号以便您搜寻文章
... including deparaffinization and antigen retrieval. For formalin-fixed paraffin-embedded tissues, antigen-retrieval is often ... Identification of B-cell lymphomas using CD20. Identification of T-cell lymphomas using CD3. PIN-4 cocktail, targeting p63, CK- ... "IHC Tip 1: Antigen retrieval - should I do PIER or HIER?". AbD Serotec. Archived from the original on 2016-04-23. Retrieved ... Visualising an antibody-antigen interaction can be accomplished in a number of ways, mainly either of the following: ...
B-cell-associated antigens such as CD19, CD20, CD22, and CD79a are usually expressed. In contrast to small lymphocytic lymphoma ... Rituximab, the anti-CD20 chimeric antibody, is a key component of therapy. Responses vary from 55% to 77% with monotherapy and ...
Nofetumomab is an antibody fragment that recognises the pancarcinoma glycoprotein antigen EpCAM. and/or CD20/MS4A1 It is the ...
... is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with ... or Transformed CD20 Positive Non-Hodgkin's Lymphoma Who Have Not Received Prior Rituximab; BEXXAR". Federal Register. 23 ...
Tedder TF, Streuli M, Schlossman SF, Saito H (1988). "Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface ... antigen of human B lymphocytes". Proc. Natl. Acad. Sci. U.S.A. 85 (1): 208-12. doi:10.1073/pnas.85.1.208. PMC 279513. PMID ... Szepetowski P, Gaudray P (1994). "FCER1B, a candidate gene for atopy, is located in 11q13 between CD20 and TCN1". Genomics. 19 ... Kanzaki M, Lindorfer MA, Garrison JC, Kojima I (1997). "Activation of the calcium-permeable cation channel CD20 by alpha ...
... is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. Therefore, it ... The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in ... It tends to stick to one side of B cells, where CD20 is, forming a cap and drawing proteins over to that side. The presence of ... ofatumumab (HuMax-CD20) a fully human B cell-depleting agent. Third-generation anti-CD20s such as obinutuzumab have a ...
Another important surface antigen is CD319 (SLAMF7). This antigen is expressed at high levels on normal human plasma cells. It ... such as CD19 and CD20. Instead, plasma cells are identified through flow cytometry by their additional expression of CD138, ... After leaving the bone marrow, the B cell acts as an antigen-presenting cell (APC) and internalizes offending antigens, which ... Pieces of the antigen (which are now known as antigenic peptides) are loaded onto MHC II molecules, and presented on its ...
... a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma5. ... the loss of tumor antigens and other molecules essential for antigen processing and presentation). Chemotherapy can promote ...
With respect to diagnosing BNS, flow cytometry analyzes CSF contents for B-cells expressing the pan antigens CD19 and CD20, ...
AME-133v is a humanized IgG1 monoclonal antibody targeting the CD20 antigen on both healthy and malignant B-lymphocytes, ... The antibody is engineered for enhanced affinity to the CD20 antigen on B-lymphocytes, increased antibody-dependent cell- ... In pre-clinical studies, ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC as ... March 2012). "Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in ...
This high mutation rate makes them prone to the selection of B-cells lacking the CD20 antigen following treatment with CD20- ... "Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression". Clinical Cancer ... B-cells that have not encountered an antigen are called naive B cells. When naïve B-cells encounter an antigen, one of the ... Approximately 95% of B-cell lymphomas express CD20, but CD20 is not critical for B-cell survival. Clonal B-cells spontaneously ...
The DLBCL cells have found to express B-cell antigens such as CD19, CD20, and CD22 as well as the transcription factors PAX5, ... CD20 is especially relevant in diagnostics as well as therapeutics because it is the target of the Rituximab humanized ... Two promising immunotherapy approaches against diffuse large B-cell lymphoma are chimeric antigen receptor (CAR) T cell therapy ...
Addition of rituximab, a monoclonal antibody against the CD20 antigen expressed on B cells, may be added to this or other ... The EBV+ large B cells in these lesions often have reduced expression of the CD20 antigen and contain genetic abnormalities ... The lymphocytes are primarily B cells (e.g., express CD20 and CD10 markers) with rare T cells evident only in the background. ... The EBV+ NK cells express CD56 antigen and are malignant with EBV in its latency II phase. The NK cells expression relatively ...
Depending on the antigen used and the genetic make-up of the animal, rodents can display a monophasic bout of EAE, a relapsing- ... "Anti-CD20 Therapy Down-Regulates Lesion Formation And Microglial Activation In Pattern I And Pattern II Rat Models Of Multiple ... Some key differences between EAE in mice, and MS in humans include: B-cells: Some research points to anti-CD20 B-cells being ... The most commonly used antigens in rodents are spinal cord homogenate (SCH), purified myelin, myelin protein such as MBP, PLP, ...
They are largely built from parts of antibodies (immunoglobulins), and like them have a binding site for antigens that could be ... Examples are TRU-015, a CD20 targeting SMIP under research for rheumatoid arthritis, and TRU-016, a CD37 targeting potential ... Rubbert-Roth, A. (2010). "TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid ... A monoclonal antibody targeting the desired antigen can be developed the classical way, using hybridoma technology. The scFv is ...
For example: pPCL plasma cells more often express CD20 antigen, which is considered important in anchoring plasma cells to the ... 17%); pPCL plasma cells often lack CD56 antigen which is present on the majority of plasma cells taken form multiple myeloma ... Examination of plasma cell immunophenotype by measuring certain of their cell surface antigens, particularly Cluster of ...
The IL-2a (CD25, T-cell activation antigen, TAC) is expressed only by the already-activated T lymphocytes. Therefore, it is of ... anti-CD20 monoclonals). Heterologous polyclonal antibodies are obtained from the serum of animals (e.g., rabbit, horse), and ... Past this period CD3 blocks the TCR-antigen binding and causes conformational change or the removal of the entire TCR3/CD3 ... The antilymphocyte (ALG) and antithymocyte antigens (ATG) are being used. They are part of the steroid-resistant acute ...
... b-lymphocyte surface antigens CD19, CD20, CD22, CD79a and FMC7, and weak expression of CD5 and CD23. Due to the similarities ... B-lymphocytes have two responsibilities: Production of antibodies - In response to antigens, B-lymphocytes produce and release ... one of its key identifiers is the absence in expression of the surface antigens CD10, CD11c, CD25, CD103 and cyclin D1 - an ... it is directed against the surface protein CD20. Case studies have documented successful treatment of B-PLL solely with ...
... is not routinely used to treat Hodgkin lymphoma due to the lack of CD20 surface antigens in most cases. The use of rituximab in ... such as CD20) are not expressed on all cells, Reed-Sternberg cells are usually of B cell origin. Although Hodgkin's is now ... lymphoma distinct from Classical Hodgkin lymphoma and is characterized by the presence of popcorn cells which express CD20. Due ... which is a monoclonal antibody against CD20) ...
... but express B cell markers like CD20, CD22, and CD79a and also express the common leukocyte antigen CD45, which is uncommon on ... The anti-CD20 monoclonal antibody Rituximab has been used in lymphocyte predominant Hodgkin lymphoma with encouraging results. ... Rituximab has specific use in treatment of NLPHL as it is a chimeric monoclonal antibody against the protein CD20. Studies ... Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20(+) form of lymphoma. Some medical organizations no ...
... antigens, cd5 MeSH D23.050.301.264.051.119 - antigens, cd19 MeSH D23.050.301.264.051.120 - antigens, cd20 MeSH D23.050.301.264. ... antigens, cd18 MeSH D23.050.301.264.035.119 - antigens, cd19 MeSH D23.050.301.264.035.120 - antigens, cd20 MeSH D23.050.301.264 ... antigens, cd18 MeSH D23.101.100.110.119 - antigens, cd19 MeSH D23.101.100.110.120 - antigens, cd20 MeSH D23.101.100.110.122 - ... antigens, cd5 MeSH D23.101.100.150.119 - antigens, cd19 MeSH D23.101.100.150.120 - antigens, cd20 MeSH D23.101.100.150.140 - ...
The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), ...
... is not routinely used to treat Hodgkin's lymphoma due to the lack of CD20 surface antigens in most cases. The use of rituximab ... For the other forms, although the traditional B-cell markers (such as CD20) are not expressed on all cells,[18] Reed-Sternberg ... Nodular lymphocyte predominant Hodgkin's lymphoma expresses CD20, and is not currently considered a form of classical Hodgkin's ... The common non-Hodgkin's treatment, rituximab (which is a monoclonal antibody against CD20) ...
... kills normal and malignant B cells that bear the CD20 antigen or the proteasome inhibitor, Bortezomib. Patients suffering type ... processing of these antigens. As they are stimulated to become plasma cells, B cells refashion parts of their genome in efforts ... and the immunoglobulin light chain antigen binding locus on the q arm of chromosome 22 at position 11.2 (i.e. 22 q11.2) by ... and recombine various genes at the immunoglobulin heavy chain antigen-binding locus on the long (i.e. "q") arm of human ...
... antibody directed against CD20 surface antigen-bearing lymphocytes) in patients with Waldenstroms macroglobulonemia). Treatment ... and hepatitic C antigen. Biopsies of skin lesions and, where indicated, kidney or other tissues can help in determining the ...
... deacetylases and histone-modifying genes are de-regulated.Bone marrow tumour cells express the following antigen targets CD20 ( ... "Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations". ...
... directed at B-cell surface antigen CD20 (D)examethasone, a glucocorticoid hormone (H)igh-dose (A)ra-C - cytarabine, an ... In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R. [R]-DHAP regimen ...
B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and ... appears to recognise a conformational variant of CD20 also known as the FMC7 antigen. CD20 is the target of the monoclonal ... CD20+antigen at the US National Library of Medicine Medical Subject Headings (MeSH) representations of the shape are found here ... Stamenkovic I, Seed B (June 1988). "Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III ...
B1b cells seem to recognize more types of antigens including intracellular antigens. Previously, B1b cell antigen recognition ... Human B1 cells have been found to have marker profile of CD20+CD27+CD43+CD70- and could either be CD5+ or CD5-, which has been ... making antibodies against antigens and acting as antigen-presenting cells. These B1 cells are commonly found in peripheral ... Hence, there appears to be a role for self or foreign antigen in shaping the repertoire of the B-1 B cell compartment. B1 B ...
Loss of tumor antigen expression is another cause of escape from immune recognition. This occurs because most tumor antigens ... Vaccinations may help the immune system locate certain oncoantigens such as MET, RET, CD20 and CD22. However; cells that evade ... Most tumor antigens are not oncoantigens, either because they are intracellular molecules, like cancer-testis antigen such as ... like the carcinoembryonic antigen (CEA) or the prostate specific antigen (PSA). Novel strategies will be required to identify ...
Surface antigens[edit]. Terminally differentiated plasma cells express relatively few surface antigens, and do not express ... common pan-B cell markers, such as CD19 and CD20. Instead, plasma cells are identified through flow cytometry by their ... Another important surface antigen is CD319 (SLAMF7). This antigen is expressed at high levels on normal human plasma cells. It ... After leaving the bone marrow, the B cell acts as an antigen presenting cell (APC) and internalizes offending antigens, which ...
CD20 • CD21 • CD22 • CD23 • CD24 • CD25 • CD26 • CD27 • CD28 • CD29 • CD30 • CD31 • CD32 (A, B) • CD33 • CD34 • CD35 • CD36 • ... 2000). "Characterization of a new member of the TNF family expressed on antigen presenting cells.". Biol. Chem. 380 (12): 1443- ... "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells.". Semin ...
This is carried out by using donor-derived antigen-presenting cells. These new methods have reduced culture time to 10-12 days ... CD20, CD21 and Immunoglobulin), natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 ( ... recurrent infections and failure of the development of antibodies on exposure to antigens. The 1999 criteria also distinguish ... selective immunoglobulin A deficiency Specific antibody deficiency to specific antigens with normal B cell and normal Ig ...
I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ... results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology. 31 (17): ...
Macrophage-1 antigen (CD11b+CD18). *VLA-4 (CD49d+CD29). *Glycoprotein IIb/IIIa (ITGA2B+ITGB3) ...
CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) • CD23 (Lumiliksimab) • CD40 (Teneliksimab, Toralizumab) • CD62L/L-selektin ( ... Induction of Potent and Long-Lasting T-Cell Responses against Cancer Antigens". Cancer Research 62: 1477-1480. ... "A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in ...
Seligman P. A., Butler C. D., Massey E. J., etal. The p97 antigen is mapped to the q24-qter region of chromosome 3; the same ... Le Beau M. M., Diaz M. O., Plowman G. D., etal. Chromosomal sublocalization of the human p97 melanoma antigen. (англ.) // Hum. ... Plowman G. D., Brown J. P., Enns C. A., etal. Assignment of the gene for human melanoma-associated antigen p97 to chromosome 3 ... Rose T. M., Plowman G. D., Teplow D. B., etal. Primary structure of the human melanoma-associated antigen p97 ( ...
The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells ... lymphoid: CD20 (Ibritumomab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab). *myeloid: CD33 ( ... They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted ...
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a ... 2001). "Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells". J. Biol. Chem. 276 ( ... CEACAM5, CD66e, CEA, carcinoembryonic antigen related cell adhesion molecule 5. External IDs. HomoloGene: 128801 GeneCards: ... Oikawa S, Nakazato H, Kosaki G (1987). "Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence". ...
The protein also carries the Jr(a) antigen, which defines the Junior blood group system.[9] ...
van Rhenen A., van Dongen G. A., Kelder A., et al. The novel AML stem cell associated antigen CLL-1 aids in discrimination ...
"Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and ...
Ebert LM, McColl SR (2002). "Up-regulation of CCR5 and CCR6 on distinct subpopulations of antigen-activated CD4+ T lymphocytes ... This receptor has been shown to be important for B-lineage maturation and antigen-driven B-cell differentiation, and it may ... dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens". J. Immunol. 167 (11): ...
"Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen". Bio/Technology. 12 ... drug were found by guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen ...
It is also called Lewis x and SSEA-1 (stage-specific embryonic antigen 1) and represents a marker for murine pluripotent stem ... CD15 Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) ... CD15 (3-fucosyl-N-acetyl-lactosamine) is a cluster of differentiation antigen - an immunologically significant molecule. CD15 ...
A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327-37. doi:10.1084 ... antigen processing and presentation of exogenous peptide antigen via MHC class II. ... antigen binding. • transmembrane signaling receptor activity. • MHC class II protein binding. Cellular component. • membrane. • ...
CD20 • CD21 • CD22 • CD23 • CD24 • CD25 • CD26 • CD27 • CD28 • CD29 • CD30 • CD31 • CD32 (A, B) • CD33 • CD34 • CD35 • CD36 • ... CD97 antigen je protein koji je kod ljudi kodiran CD97 genom.[1][2][3] ... 2001). "Tissue distribution of the human CD97 EGF-TM7 receptor". Tissue Antigens 57 (4): 325-31. PMID 11380941. doi:10.1034/j. ... "Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of ...
Rituksimab, brend Rituxan® i MabThera®, je anti-CD20 monoklonalno antitelo koje je ranije korišćeno protiv carcinoma. Pokazano ... veoma kasan antigen -4). Rezultati faze IIa su objavljeni. ... a second-generation anti-CD20 monoclonal antibody, for the ... Usled nepovoljnog profila nuspojava i postojanja boljih anti-CD20 lekova[20], dalja ispitivanja Rituksimaba su bila ograničena ... Hutas G (November 2008). "Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell ...
Unlike virtually all other mammals, humans and other primates do not make αGal, and in fact recognize it as an antigen.[12] ... Monoclonal anti-CD20 antibodies *Rituximab. Blood transfer[edit]. Cases refractory to immunosuppressive or antibody therapy are ... An animal's exposure to the antigens of a different member of the same or similar species is allostimulation, and the tissue is ... In the living donor, such presentation of self antigens helped maintain self tolerance.) Thereupon, the T cell receptors (TCRs ...
CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) • CD23 (Lumiliksimab) • CD40 (Teneliksimab, Toralizumab) • CD62L/L-selektin ( ... ćelije bile identifikovane kao najpotentniji proizvođači tipa I interferona u odgovoru na antigen, i bile su nazvani prirodne ...
"Entrez Gene: ITGB3 integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)".. *^ May, K. E.; Villar, J.; Kirtley, S.; ... CD61+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ...
An anti-CD20 antibody, rituximab, inhibits B cells and has been shown to provoke C-peptide responses three months after ... that suppress activation of the immune system and thereby maintain immune system homeostasis and tolerance to self-antigens.[26 ...
... s gegen den B-Zell-Böverflachenmarker CD20 kennt blots naive (d.h. de noch keen Antigen kennt hebbt) un Gedächtnis-B- ... De hoge Spezifität, mit de Antikörpers jemehr Antigen kennt, warrt in de Biologie utnütt, üm dat Antigen, wat in de meisten ... Biorama.ch: Antigen - Antikörper - Binnen. Literatur[ännern , Bornkood ännern]. *Alexander H. Lucas (2001): Immunoglobulin Gene ... Antigen-Antikörper-Binnen[ännern , Bornkood ännern]. Antikörpers binnt mit jemehr A(ntigen)B(inding)-Rebeet „jemehr" Epitop ...
CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) • CD23 (Lumiliksimab) • CD40 (Teneliksimab, Toralizumab) • CD62L/L-selektin ( ... Nakon presađivanja (transplantacije) organa, telo skoro uvek „odbaci" novi organ usled razlike ljudskih leukocit antigen ...
... is not routinely used to treat Hodgkin lymphoma due to the lack of CD20 surface antigens in most cases. The use of rituximab in ... For the other forms, although the traditional B-cell markers (such as CD20) are not expressed on all cells,[23] Reed-Sternberg ... The common non-Hodgkin treatment, rituximab (which is a monoclonal antibody against CD20) ... lymphoma distinct from Classical Hodgkin lymphoma and is characterized by the presence of popcorn cells which express CD20.[22] ...
"Direct association of adenosine deaminase with a T cell activation antigen, CD26". Science. 261 (5120): 466-9. doi:10.1126/ ...
B cells can present antigens to a specialized group of helper T cells called TFH cells. If an activated TFH cell recognizes the ... Roles of T cell-B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help". Journal of Immunology. 149 (12): ... It binds to CD40 (protein) on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. In ... Grewal, IS; Xu, J; Flavell, RA (7 December 1995). "Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand". ...
antigen processing and presentation of peptide antigen via MHC class I. • antigen processing and presentation of exogenous ... antigen processing and presentation of exogenous peptide antigen via MHC class I. • lipoprotein transport. • negative ... peptide antigen via MHC class I, TAP-dependent. • platelet degranulation. • MyD88-dependent toll-like receptor signaling ...
Despite the clinical success of CD20-specific antibody rituximab, malignancies of B-cell origin continue to present a major ... CD20 scFv antibody Natural killer cell Chimeric antigen receptor Adoptive therapy Electronic supplementary material. The online ... and CD20-positive NIH3T3-CD20(eGFP), and eGFP- and CD20-negative NIH3T3 cells before addition of NK cells is shown. Exemplary ... Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of ...
CD20" by people in this website by year, and whether "Antigens, CD20" was a major or minor topic of these publications. ... "Antigens, CD20" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Below are the most recent publications written about "Antigens, CD20" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Antigens, CD20". ...
The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle.. J T Golay, E A ... The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. ... The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. ... The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. ...
Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation ... Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation ... Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation ... Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation ...
The CD20 antigen displays a unique expression pattern among hematopoietic cells - it is present on human pre B-lymphocyte ... CD20 is a human B-lymphocyte surface molecule that spans the membrane four times and is expressed on both normal and malignant ... The CD20 antigen displays a unique expression pattern among hematopoietic cells - it is present on human pre B-lymphocytes and ... Western Blot: CD20 Antibody. Expression and biochemistry studies with the CD20 antibody from Uchidas lab at Duke were ...
Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or ... CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot ... The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell ... Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21):2008-16.View ArticleGoogle Scholar. ...
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell ... Clinical trial focusing on CD20 positive lymphoma and mantle cell lymphoma. ... Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and ... Clinical Trial: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and ...
Home , A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells ... 2015) A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. ...
Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. I ... Two cDNA clones encoding the pan-B cell CD20 antigen were isolated from a COS cell expression library. The two clones bear ... I Stamenkovic, B Seed; Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral ... The predicted CD20 sequence is 297 residues long and contains three hydrophobic domains, one of which is long enough to span ...
... antigen)) (mouse monoclonal clone B1R1 γ2a-chain), disulfide with mouse monoclonal clone B1R1 λx-chain, dimer, iodine-131I salt ... CA Index Name: Immunoglobulin G2a, anti-(human CD20 (antigen)) (mouse monoclonal clone B1R1 γ2a-chain), disulfide with mouse ...
Development of a Mimotope-Based Vaccine Against CD20 Antigen. Author(s): Meng Li, Wei Han, Quiyang Zhang, Xiaochang Xue, Zenglu ... CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to ... Abstract: CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of ... Keywords: CD20, mimotope, vaccine, B-cell lymphoma, immunotherapy, keyhole limpet hemocyanin (KLH) ...
CD20, CD56) - This anti-Human Lineage Cocktail is optimized for the detection of human lymphocytes, monocytes, eosinophils, and ... This cocktail is composed of CD3, CD14, CD19, CD20, and CD56. CD3 is the antigen mainly found on T cells; CD14 is expressed on ... Antigen References 1. Zola H, et al. Eds. 2007. Leukocyte and Stromal Cell Molecules. New Jersey. 2. Olweus J, et al. 1997. P. ... CD19 and CD20 are expressed on B lymphocytes. CD56 is expressed on activated and resting NK lymphocytes. Cell Type T cells, ...
CD20, CD56) - This anti-Human Lineage Cocktail is optimized for the detection of human peripheral blood T cells, B cells, NK ... This cocktail is composed of CD3, CD14, CD16, CD19, CD20, and CD56. CD3 is the antigen mainly found on T cells; CD14 is ... Antigen Details Distribution T cells, B cells, NK cells, monocytes/macrophages, neutrophils ... CD19 and CD20 are on B cells; CD56 is located on NK cells. ... APC anti-human Lineage Cocktail (CD3, CD14, CD16, CD19, CD20, ...
These data support the concept that in B-CLL rituximab treatment may not lead to the emergence of CD20(-) leukemic variants. ... Antigens, CD20 / genetics* * Antineoplastic Agents / therapeutic use* * Base Sequence * DNA Primers * Gene Expression ... Results: Cytotoxicity of rituximab in vitro did not depend on the protein levels of CD20. During therapy with rituximab CD20 ... After treatment, the initial CD20(+) B-CLL cell clone reexpanded. CD20(-) B-CLL cells retained their capacity to synthesize the ...
Rituximab, a chimaeric anti-CD20 monoclonal antibody, has been demonstrated to be highly effective for in vivo B-cel … ... Antigens, CD20 / immunology* * B-Lymphocytes / immunology * Female * Humans * Immunoglobulins, Intravenous / administration & ... Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus ... Rituximab, a chimaeric anti-CD20 monoclonal antibody, has been demonstrated to be highly effective for in vivo B-cell depletion ...
Shop a large selection of products and learn more about CD20 Mouse anti-Human, Biotin, Clone: 2H7, eBioscience 100 µg; Biotin ... employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. After the receptor ligation, BCR and ... CD20 has been detected at low levels on a small subset of mature T cells. It is suggested that CD20 plays a role in B-cell ... CD20 is expressed on mature and most maligt B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. CD20 ...
Shop a large selection of products and learn more about CD20, Mouse anti-Human, Clone: 2H7, BV650, BD 25 Tests; BV650 25 Tests ... Antigen. CD20. Format. Affinity Purified. Immunogen. Human 6.16c1.3 B cell line. ...
Antigen. Clone. Source. CD20. FLEX CD20cy, MxH L26. Dako Autostainer Plus (Dako, Carpinteria, CA). ...
Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an ... First in class CAR treatment targeting both CD19 and CD20 simultaneously. *Simultaneous targeting of two antigens decreases the ... B Cell Malignancies, Leukemia, Lymphoma, CD19, CD20, Bicistronic, Adoptive Cell Therapy, ACT, Chimeric Antigen Receptor, CAR, ... Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an ...
Consistently, we observed that human CD20 is a high immunogenic antigen because human CD20-expressing A20 tumors were ... Rituximab is a murine-human chimeric IgG1 Ab that recognizes the human CD20 antigen on B cells, with a primary response rate ... To determine whether the cross-presentation function of APC is enhanced after anti-CD20 treatment, we transfected an antigen ... Production of anti-mouse CD20 Ab. The V region of the heavy chain and light chain of anti-mouse CD20 Ab was linked with a ...
... dc.contributor.advisor. Deans, ... Petrie, R. J. (2002). Involvement of lipid rafts in the membrane dynamics of CD20 and the B cell antigen receptor (Unpublished ... Involvement of lipid rafts in the membrane dynamics of CD20 and the B cell antigen receptor. ...
CD20-like family (IPR007237) *Membrane-spanning 4-domains subfamily A (IPR030417) *B-lymphocyte antigen CD20 (IPR030418) ... MS4A1 (B-lymphocyte antigen CD20) [PMID: 20038800], MS4A2 (high affinity IgE receptor subunit beta) [PMID: 16272347, PMID: ... Membrane-spanning four-domains subfamily A (MS4A) includes B-cell-specific antigen CD20 (MS4A1), high affinity immunoglobulin ... CD20 deficiency in humans results in impaired T cell-independent antibody responses.. J. Clin. Invest. 120 214-22 2010 ...
CD20 was chosen as the target tumor antigen for initial proof-of-concept studies as rituximab, an anti-CD20 antibody, has been ... CD20-2GL-SIRPα HC: (GGGGS)2, CD20-4GL-SIRPα HC: (GGGGS)4, SIRPα-γ-CD20 HC: ASTKGPSVFPLAP. Plasmids containing each chain were ... with SIRPα-γ-CD20 HC having an approximately 20-fold reduction and CD20-2GL-SIRPα HC and CD20-4GL-SIRPα HC having more than 50- ... In contrast, CD20-2GL-SIRPα HC and CD20-4GL-SIRPα HC each had reduced binding to CD47 relative to SIRPα-Fc, presumably due to ...
Mouse monoclonal CD20 antibody [B-H20]. Validated in Flow Cyt and tested in Human. Immunogen corresponding to tissue, cells or ... recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of ... also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, ...
Mouse monoclonal CD20 antibody [2H7] conjugated to PerCP. Validated in Flow Cyt and tested in Human, Non human primates. Cited ... recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of ... Anti-CD20 antibody [2H7], prediluted (Allophycocyanin) (ab134334) *Anti-CD20 antibody [2H7], prediluted (PerCP/Cy5.5®) ( ... Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment.. J Biol Chem 273:344-8 (1998). Read ...
Antigen Expression CD19 +; CD20 +; CD21 +; CD22 +; Hle-1 +; HLA DQ +; HLA DR +; CD25 -; T cell receptor (TCR) - ...
Antigen Expression CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 ... CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -. Comments The BC-3 cell line contains the viral genome for Kaposis sarcoma- ... The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage- ...
... marneffei infection in 4 hematology patients without AIDS who received targeted therapy with monoclonal antibodies against CD20 ... A serum cryptococcal antigen test result was negative. He was empirically given intravenous imipenem/cilastatin and oral ... D. Recent emergence of disseminated T. marneffei infection is most likely because of targeted therapies, such as anti-CD20 ... Rituximab and obinutuzumab (used by case-patients cases 1 and 2) are mAbs against CD20 that predominantly target B cells. ...
Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients ... The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on ... Target-mediated elimination rate constant increased with the baseline CD20 count on circulating B cells (p = 0.00046) and in ... Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic ...
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory ... patients mainly due to antigen loss. The authors performed a phase Ⅱ trial by coadministration of anti-CD19 and anti-CD20 CAR-T ... The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti-CD19 and anti-CD20 CAR-T cells ... PURPOSE: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy for refractory and ...
  • Despite the clinical success of CD20-specific antibody rituximab, malignancies of B-cell origin continue to present a major clinical challenge, in part due to an inability of the antibody to activate antibody-dependent cell-mediated cytotoxicity (ADCC) in some patients, and development of resistance in others. (springer.com)
  • The anti-CD20 monoclonal antibody (mAb) rituximab (RTX) was the first chimeric mAb approved for therapy. (novusbio.com)
  • A paper discussing mechanisms of action as well as resistance to rituximab cites use of the CD20 antibody (2). (novusbio.com)
  • More detailed rituximab resistance studies from Henry et al employed the CD20 antibody to analyze alternative CD20 transcripts that encode a newly identified DeltaCD20 protein that may play an important role in resistance (3). (novusbio.com)
  • In the present study, we investigated whether rituximab therapy may select for CD20(-) subclones. (nih.gov)
  • Cytotoxicity of rituximab in vitro did not depend on the protein levels of CD20. (nih.gov)
  • During therapy with rituximab CD20(+) B-CLL cells were depleted and CD20(-) leukemic cells emerged. (nih.gov)
  • These data support the concept that in B-CLL rituximab treatment may not lead to the emergence of CD20(-) leukemic variants. (nih.gov)
  • Rituximab, a chimaeric anti-CD20 monoclonal antibody, has been demonstrated to be highly effective for in vivo B-cell depletion. (nih.gov)
  • Rituximab (anti-CD20 antibody), the first mAb used for cancer therapy, was approved by the FDA for treating non-Hodgkin B-cell lymphoma nearly 20 years ago. (aacrjournals.org)
  • Agents that block the CD47-SIRPα interaction synergize with pro-phagocytic FcR-activating antibodies, including the anti-CD20 antibody rituximab, for potent phagocytic elimination of tumor cells. (aacrjournals.org)
  • Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocyti. (cdc.gov)
  • Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). (cdc.gov)
  • Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. (cdc.gov)
  • The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab pharmacokinetics in CLL. (cdc.gov)
  • Rituximab pharmacokinetics was described in 118 CLL patients using a semi-mechanistic model including a latent target antigen turnover, which allowed the estimation of rituximab target-mediated elimination in addition to the endogenous clearance. (cdc.gov)
  • A pharmacokinetic model including target-mediated elimination accurately described rituximab concentrations in CLL and showed that rituximab 'consumption' (target-mediated elimination) increases with increasing baseline antigen count on circulating B cells and in FCGR3A-158VV patients. (cdc.gov)
  • Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. (medscape.com)
  • 3 12 - 18 Rituximab is a chimeric monoclonal antibody against CD20, a B cell-specific surface marker. (bmj.com)
  • To evaluate changes in cluster of differentiation (CD)20 antigen expression and density of expression in patients receiving Pegfilgrastim and rituximab. (clinicaltrials.gov)
  • Rituximab is a chimeric monoclonal antibody that targets B-cell surface antigen CD20 and can cross the placenta. (aappublications.org)
  • Rituximab is a chimeric monoclonal antibody directed against B-cell surface antigen CD20. (aappublications.org)
  • Rituximab administration results in depletion of peripherally circulating CD20-expressing B cells. (aappublications.org)
  • Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of pre-B and mature B-lymphocytes. (drugs.com)
  • Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells. (genetex.com)
  • Rituximab, a chimeric monoclonal antibody against the CD20 antigen, has been approved since 2006 for the treatment of patients with rheumatoid arthritis. (iospress.com)
  • Rituximab was the first approved anti-CD20 monoclonal antibody. (lymphomacoalition.org)
  • Rituximab binds to CD20, a protein found on B cells, resulting in the killing of cancer cells. (lymphomacoalition.org)
  • Rituxan/Mabthera (rituximab) is a chimeric human/murine monoclonal antibody targeting the CD20 antigen expressed on the surface of B cells. (sartorius.com)
  • Two monoclonal antibodies, 1F5 and B1, directed against the CD20 (Bp35) antigen were found to have both stimulatory and inhibitory effects on B cells. (jimmunol.org)
  • CD20 is a B cell-specific 35/37 kDa integral membrane protein which modulates proliferation and differentiation of normal resting B cells when stimulated by CD20 antibodies. (jimmunol.org)
  • Then T cells are activated with anti-human CD3/CD28 antibody-coated beads, anti-CD3 monoclonal antibodies, and/or artificial antigen-presenting cells(APCs). (biomedcentral.com)
  • Our bispecific antibodies incorporate a blocking component with weak affinity for CD47, rendering them unable to bind normal cells expressing CD47 alone, and require simultaneous binding to CD20 for high avidity binding to dual antigen-expressing tumor cells. (aacrjournals.org)
  • Such bispecific antibodies targeting CD47 along with tumor-associated antigens may be an effective strategy for selectively eliminating tumor cells that can be broadly applied to cancer. (aacrjournals.org)
  • We report disseminated T. marneffei infection in 4 hematology patients without AIDS who received targeted therapy with monoclonal antibodies against CD20 or kinase inhibitors during the past 2 years. (cdc.gov)
  • No antibodies against prostate-specific antigen were detected. (aacrjournals.org)
  • In vitro effects of CD20-specific antibodies on resting B cells indicate that CD20 is able to transduce an extracellular signal affecting the G0/G1 cell cycle transition. (miltenyibiotec.com)
  • Doctors can also use other monoclonal antibodies that target CD20. (webmd.com)
  • Examples are lymphoma antibodies hitting CD20, CD30, CD52. (halfbakery.com)
  • Those antibodies also kill the normal lymphocytes with those antigens, with the ill effects dependent on how important those normal ones are. (halfbakery.com)
  • It involves the process of selectively identifying antigens (proteins) in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues. (wikipedia.org)
  • Although antibodies show preferential avidity for specific epitopes, they may partially or weakly bind to sites on nonspecific proteins (also called reactive sites) that are similar to the cognate binding sites on the target antigen. (wikipedia.org)
  • Primary antibodies are raised against an antigen of interest and are typically unconjugated (unlabeled), while secondary antibodies are raised against immunoglobulins of the primary antibody species. (wikipedia.org)
  • http://www.ixsbio.com ), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the completion of a large scale primate study confirming effectiveness and safety of its lead candidate DXL625 (CD20). (bio-medicine.org)
  • They are B cells, which react with monoclonal antibodies against B cells (CD20, CD22 and CD24). (medscape.com)
  • We consider the implications of this case series and outline potential considerations in the long-term use of anti-CD20 monoclonal antibodies in NMO and other neuroinflammatory diseases. (springer.com)
  • All monoclonal antibodies directed to the extracellular domain of the CD20 molecule are likely to bind closely related epitopes. (beckman.com)
  • Cell surface antigens can stimulate the production of antibodies by B lymphocytes and cytotoxic responses by white blood cells, e.g., granulocytes, monocytes, and lymphocytes. (tabers.com)
  • This exposure activates the lymphocytes to produce antibodies, which are immune system factors that target and attack specific foreign proteins (antigens). (stlukes-stl.com)
  • Toxins attached to growth factors, antibodies and other cell targeting molecules can be used to kill harmful cells bearing specific receptors or antigens (Pastan et al. (google.com)
  • Here we have generated genetically modified NK cells carrying a chimeric antigen receptor that consists of a CD20-specific scFv antibody fragment, via a flexible hinge region connected to the CD3ζ chain as a signaling moiety. (springer.com)
  • Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. (biomedcentral.com)
  • Recently, chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed. (biomedcentral.com)
  • CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation. (fishersci.com)
  • After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface. (fishersci.com)
  • Membrane-spanning four-domains subfamily A (MS4A) includes B-cell-specific antigen CD20 (MS4A1), high affinity immunoglobulin epsilon receptor beta chain (MS4A2), hematopoietic-cell-specific protein HTm4 (MS4A3), and related proteins. (ebi.ac.uk)
  • Identification of a new multigene four-transmembrane family (MS4A) related to CD20, HTm4 and beta subunit of the high-affinity IgE receptor. (ebi.ac.uk)
  • The mouse monoclonal antibody 2H7 recognizes CD20 (B1, Bp35), a 33-37 kDa non-glycosylated membrane receptor with four transmembrane domains, expressed on pre-B lymphocytes, resting and activated B cells (not plasma cells), follicular dendritic cells, and at low levels on peripheral blood T lymphocytes. (abcam.com)
  • PURPOSE: Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has demonstrated remarkable efficacy for refractory and relapsed diffuse large B cell lymphoma (R/R DLBCL). (omgcb.com)
  • Just as heat-seeking missiles race toward the infrared signatures of their targets, chimeric antigen receptor (CAR) T cells home in on cancer-associated or -specific antigens. (genengnews.com)
  • We highlight cutting-edge immunotherapeutic strategies in preclinical and clinical development such as adoptive NK cell transfer, chimeric antigen receptor-expressing NK cells (CAR-NKs), bispecific and trispecific killer cell engagers (BiKEs and TriKEs), checkpoint blockade, and oncolytic virotherapy. (jci.org)
  • The vector of anti-CD20 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD20. (creative-biolabs.com)
  • CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). (creative-biolabs.com)
  • CD20 may also exist on the cell surface as a homo-oligomeric complex forming with other molecules a multimeric receptor complex. (beckman.com)
  • Traceless aptamer-mediated isolation of CD8 + T cells for chimeric antigen receptor T-cell therapy. (nih.gov)
  • Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. (nih.gov)
  • Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion. (nih.gov)
  • An autologous form of cellular immunotherapy - chimeric antigen receptor (CAR) T-cell therapy - is currently under investigation. (lymphomacoalition.org)
  • The principle of both Rituxan ADCC and CDC assays is that the relevant target cells, typically Raji, Daudi, or Ramos cells, expressing the CD20 protein are prepared in cell plates using a procedure designed to optimize receptor expression. (sartorius.com)
  • Chimeric antigen receptor T cells (also known as CAR T cells) are T cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy. (wikipedia.org)
  • Chimeric antigen receptors (CARs, also known as chimeric immunoreceptors, chimeric T cell receptors or artificial T cell receptors) are receptor proteins that have been engineered to give T cells the new ability to target a specific protein. (wikipedia.org)
  • The receptors are chimeric because they combine both antigen-binding and T-cell activating functions into a single receptor. (wikipedia.org)
  • A first generation CAR containing a CD4 extracellular domain and a CD3ζ intracellular domain was used in the first clinical trail of chimeric antigen receptor T cells by the biotechnology company Cell Genesys in the mid 1990s, allowing adoptively transferred T cells to target HIV infected cells, although it failed to show any clinical improvement. (wikipedia.org)
  • The CD20 antigen displays a unique expression pattern among hematopoietic cells - it is present on human pre B-lymphocytes and B-lymphocytes at all stages of maturation (except for plasma cells). (novusbio.com)
  • Low CD20 antigen expression levels have been detected on normal T-lymphocytes. (novusbio.com)
  • CD19 and CD20 are expressed on B lymphocytes. (biolegend.com)
  • CD20 is expressed on mature and most maligt B cells, in a subpopulation of T lymphocytes and follicular dendritic cells. (fishersci.com)
  • Ofatumumab is a novel monoclonal antibody (mAb) that specifically binds to the human CD20 antigen, which is expressed only in B lymphocytes. (clinicaltrials.gov)
  • Binds to the CD20 antigen which is found on mature B lymphocytes. (drugbank.ca)
  • The complementarity-determining regions of Ibritumomab bind to the CD20 antigen on B lymphocytes. (centerwatch.com)
  • The candidate was effective in completely eliminating all lymphocytes with a CD20 marker within hours at the lowest dose tested. (bio-medicine.org)
  • CD20 is expressed by B lymphocytes and by a small subset of normal circulating T lymphocytes. (lsbio.com)
  • The CD20 molecule is present on all B lymphocytes whatever the hematopoietic tissue where they are found (peripheral blood, lymph nodes, spleen, tonsil, or bone marrow). (beckman.com)
  • The CD20 antigen may be weakly expressed on a subset of resting T lymphocytes. (beckman.com)
  • In lymph nodes, lymphocytes receive their initial exposure to foreign substances (antigens), such as bacteria or other microorganisms. (stlukes-stl.com)
  • CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. (springer.com)
  • The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. (jimmunol.org)
  • Analysis of two cDNA clones encoding the B lymphocyte antigen CD20 (B1, Bp35), a type III integral membrane protein. (rupress.org)
  • The CD20 antigen (Bp35) is an integral non-glycosylated membrane protein with four transmembrane domains. (beckman.com)
  • Expression of chimeric antigen receptors in effector cells operative in ADCC might allow to bypass insufficient activation via FcγRIII and other resistance mechanisms that limit natural killer (NK)-cell activity. (springer.com)
  • While activity of the retargeted NK-92 against CD20-negative targets remained unchanged, the gene modified NK cells displayed markedly enhanced cytotoxicity toward NK-sensitive CD20 expressing cells. (springer.com)
  • Importantly, in contrast to parental NK-92, CD20-specific NK cells efficiently lysed CD20 expressing but otherwise NK-resistant established and primary lymphoma and leukemia cells, demonstrating that this strategy can overcome NK-cell resistance and might be suitable for the development of effective cell-based therapeutics for the treatment of B-cell malignancies. (springer.com)
  • Supplementary Fig. S1 Recombinant scFv(Leu-16) binds to CD20 expressing lymphoma cells. (springer.com)
  • c Binding of recombinant scFv molecules to CD20 expressing but ErbB2-negative Raji lymphoma cells (upper panel), and ErbB2 expressing but CD20-negative SKBR3 breast carcinoma cells was analyzed by flow cytometry with Myc-tag specific Mab 9E10 and FITC-conjugated secondary antibody. (springer.com)
  • NK-92-scFv(Leu-16)-ζ cells were incubated with 100 μM of the serine protease inhibitor DCI (3,4-dichloroisocoumarin) (Roche, Mannheim, Germany) in X-VIVO 10 medium for 1 h at 37°C, before their cytotoxic activity towards CD20 expressing NIH3T3-CD20 cells was analyzed in a 3 h MTT cytotoxicity assay as described in the methods section (E/T ratio of 10:1). (springer.com)
  • CD20 is a human B-lymphocyte surface molecule that spans the membrane four times and is expressed on both normal and malignant cells. (novusbio.com)
  • COS cells transfected with either CD20 clone express an immunoreactive protein of 33 kD. (rupress.org)
  • CD20(-) B-CLL cells retained their capacity to synthesize the CD20 molecule. (nih.gov)
  • CD20 is expressed by developing B cells as well as mature B cells but not plasma cells. (fishersci.com)
  • CD20 has been detected at low levels on a small subset of mature T cells. (fishersci.com)
  • CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation. (fishersci.com)
  • CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell maligcies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment. (fishersci.com)
  • The purpose of this study was to explore whether T cells are involved in mediating the effects of anti-CD20 therapy and what factors contribute to adaptive immune response-related resistance. (aacrjournals.org)
  • Using a syngeneic mouse B-cell lymphoma model, we investigated the role of CD8 + T cells in anti-CD20-mediated tumor regression. (aacrjournals.org)
  • CD8 + T cells played an essential role in anti-CD20-mediated tumor regression. (aacrjournals.org)
  • A potential limitation of therapeutic CD47-SIRPα antagonists is that expression of CD47 on normal cells may create sites of toxicity or an "antigen sink. (aacrjournals.org)
  • SIRPabodies selectively bound to dual antigen-expressing tumor cells in the presence of a large antigen sink. (aacrjournals.org)
  • We developed bispecific antibody variants targeting CD47 and CD20 to combine these two functions into a single molecule that recapitulated the potent synergistic effect of combination therapy with no toxic effects on normal cells. (aacrjournals.org)
  • The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage-restricted antigens. (atcc.org)
  • The cells do express activation antigens. (atcc.org)
  • Target-mediated elimination rate constant increased with the baseline CD20 count on circulating B cells (p = 0.00046) and in patients with the FCGR3A-158VV genotype (p = 0.0016). (cdc.gov)
  • The authors performed a phase Ⅱ trial by coadministration of anti-CD19 and anti-CD20 CAR-T cells treatment for R/R DLBCL and evaluated its efficacy and toxicity. (omgcb.com)
  • The patients were conditioned with fludarabine and cyclophosphamide before the infusion of anti-CD19 and anti-CD20 CAR-T cells. (omgcb.com)
  • Peak levels of anti-CD19 and anti-CD20 CAR cells were associated with response (P = .007 and .002). (omgcb.com)
  • CONCLUSIONS: Coadministration of anti-CD19 and CD20 CAR-T cells therapy for DLBCL is feasible with manageable toxicity. (omgcb.com)
  • The agents in this class target specific antigens in carcinoma cells and induce cytotoxicity. (medscape.com)
  • Unfortunately, killer T cells often fail to distinguish cancer cells-which is why T cells are being equipped with synthetic receptors known as chimeric antigen receptors, or CARs, that are designed to latch onto antigens that stud cancer cells but are seldom (or never) seen on healthy cells. (genengnews.com)
  • Once the antigens are engaged, CAR T cells let fly with cytotoxic flak, granules containing perforin and granzymes, while activating supplementary tumor-killing mechanisms such as stromal sensitization and macrophage polarization. (genengnews.com)
  • In addition, activation of T cells is partially controlled by B cell antigen presentation. (bmj.com)
  • CD20 is present on B cells from early development through maturity until the differentiation of B cells into plasma cells. (bmj.com)
  • Because many such antigens may also be present in normal prostate epithelial cells as well as PCA cells, one major therapeutic challenge for induction of anti-PCA immune responses may be the need to overcome immune tolerance against normal prostate antigens. (aacrjournals.org)
  • Irradiated GM-CSF-secreting cancer cell vaccines induce antitumor immune responses by recruiting antigen-presenting cells, such as DCs, to immunization sites. (aacrjournals.org)
  • This approach, termed antigen-specific immunosuppression, involves vaccinating with β-cell proteins so that β-cell-specific T cells do not subsequently respond to and attack them ( 6 ). (diabetesjournals.org)
  • Clone REA1087 recognizes an intracytoplasmic epitope localized on the CD20 antigen, which is a non-glycosylated transmembrane protein of 33-37 kDa that is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. (miltenyibiotec.com)
  • The antigen is further expressed on most malignant B cells. (miltenyibiotec.com)
  • CD20 is not found on early B cell progenitors or plasma cells. (miltenyibiotec.com)
  • LT20 recognizes the CD20 antigen, a non-glycosylated transmembrane protein of 33-37 kDa that is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. (miltenyibiotec.com)
  • This inspired our hypothesis that an immunocytokine that targets CD20 and a second highly expressed antigen on such malignant cells could be even more efficacious. (aacrjournals.org)
  • The bispecific immunocytokine may be particularly effective in the elimination of the putative cancer stem cells associated with myeloma, which are resistant to current therapy regimens and reportedly express CD20. (aacrjournals.org)
  • Your doctor will get your lymphoma cells tested to see if they have certain markers -- proteins called antigens. (webmd.com)
  • You'll get a monoclonal antibody drug that aims at the antigens found on your lymphoma cells. (webmd.com)
  • They're designed to lock onto certain antigens that cancer cells make too much of. (webmd.com)
  • They then carry these cell-killing materials to the cancer cells and lock onto the antigen. (webmd.com)
  • This leads to the death of the cancer cells, with little to no effect on your normal cells that don't have the antigen. (webmd.com)
  • You might get a monoclonal antibody that targets a different antigen that's found on your lymphoma cells. (webmd.com)
  • For instance, you may get alemtuzumab (Campath) if your cells have the CD52 antigen. (webmd.com)
  • Your lymphoma cells might have the CD30 antigen, in which case brentuximab vedotin ( Adcetris ), a monoclonal antibody attached to chemo, might be part of your treatment plan. (webmd.com)
  • Pre- and mature B-cells, characterized by CD20 antigen expression, play an important role in the inflammatory process. (iospress.com)
  • The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD20 antibody linked to CD28 transmembrane domain/ endodomain and CD3-zeta signaling domains. (creative-biolabs.com)
  • The current study assessed the impact of various selenocompounds on the expression of HLA class I molecules in THP-1 cells, an apparent proficient antigen that pres. (medworm.com)
  • The CD3 antigen is present on the cell membrane of normal T cells and is expressed in the majority of T-cell neoplasms. (osu.edu)
  • CD20 is expressed in normal and neoplastic B cells. (osu.edu)
  • Also referred to as MART1 (Melanoma Antigen Recognized by T cells). (osu.edu)
  • Factor VIII-realted antigen (vonWillebrand factor) is present in endothelial cells and in the cytoplasm of megakaryocytes. (osu.edu)
  • CD4 + cells from OT-II Thy1.1 + mice or CD8 + cells from OT-I Thy1.1 + mice were CFSE-labeled and transferred into Thy1.2 + recipients that had been treated with CD20 or control mAb 7 days earlier. (pnas.org)
  • The problem with this is that cancer cells are very diverse, so it's very difficult to find a cancer-specific antigen that's found in all cancer cells. (halfbakery.com)
  • However, cancer cells are derived from non-cancer cells, which *do* have specific antigens that can be used. (halfbakery.com)
  • This is contingent upon two things - (1) that specific tissues can be targeted, and (2) that cancer cells retain tissue specific antigens. (halfbakery.com)
  • After infusion into a patient, the monoclonal antibody targets the CD20 antigen, which is found on the surface of mature B cells and B-cell tumors. (centerwatch.com)
  • This study confirms that DXL625 is specific to the CD20 antigen present on NHL tumor cells and is a major milestone in our plan for clinical and commercial success," said Jeff Morhet, CEO and Chairman of InNexus. (bio-medicine.org)
  • The CD20 marker is the same as that found on tumors cells in patients with Non-Hodgkins Lymphoma patients. (bio-medicine.org)
  • [ 2 , 3 ] This zone contains postfollicular memory B cells derived after stimulation of recirculating cells by T-cell-dependent antigen. (medscape.com)
  • The expression of CD20 is restricted to B-lineage cells. (beckman.com)
  • However, CD20 is not expressed on other leucocyte subsets including NK cells, monocytes and granulocytes. (beckman.com)
  • Antigens on the body's own cells are called autoantigens. (tabers.com)
  • Antigens on all other cells are called foreign antigens. (tabers.com)
  • Reactions to antigens by T and B cells are part of the specific immune response. (tabers.com)
  • Cell-Templated Silica Microparticles with Supported Lipid Bilayers as Artificial Antigen-Presenting Cells for T Cell Activation. (nih.gov)
  • The commitment of naive CD8 T cells to effector or memory cell fates can occur after a single day of antigenic stimulation even though virus-derived antigens (Ags) are still presented by DCs long after acute infection is resolved. (rupress.org)
  • Antigen (Ag) processing and presentation is essential for the activation and differentiation of T cells. (rupress.org)
  • Rituxan mediates its activity through the interaction with the protein CD20, found on the surface of B cells. (sartorius.com)
  • Once isolated from a person, these T cells are genetically engineered to express a specific CAR, which programs them to target an antigen that is present on the surface of tumors. (wikipedia.org)
  • For safety, CAR-T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells. (wikipedia.org)
  • When they come in contact with their targeted antigen on a cell, CAR-T cells bind to it and become activated, then proceed to proliferate and become cytotoxic. (wikipedia.org)
  • Similar early clinical trials of CAR T cells in solid tumors in the 1990s using first generation CARs targeting a solid tumor antigens such as MUC1 did not show long term persistence of the transferred T cells or result in significant remissions. (wikipedia.org)
  • Additionally, the CD20 antibody allowed Berzi's lab to probe the role of brain-derived growth factor (BDNF) and its associated receptors in determining thymus cell fate (5). (novusbio.com)
  • Unlike physiological T cell receptors (TCR), scFv can recognize antigen directly without major histocompatibility complex (MHC) restriction. (biomedcentral.com)
  • Chimeric Antigen Receptors (CARs) are engineered proteins that can be used in a therapeutic capacity when expressed by an immune cell (e.g., a T cell). (cancer.gov)
  • The invention relates to bispecific tetravalent receptors of the formula I ##STR1## or formula II ##STR2## against a tumor-associated antigen and against an agent active against tumors. (google.com)
  • Levels of CD20 protein and mRNA were determined using flow cytometry and real-time PCR, respectively. (nih.gov)
  • After treatment, the initial CD20(+) B-CLL cell clone reexpanded. (nih.gov)
  • The epitope recognized by clone 2H7 has been mapped to the following sequence found in the large extracellular loop of human CD20: YNCEPANPSEKNSPST. (genetex.com)
  • Furthermore it appears that Mouse anti Human CD20 antibody, clone 2H7 only recognizes human CD20 in its native oligomeric form (Polyak et al. (genetex.com)
  • Expression and biochemistry studies with the CD20 antibody from Uchida's lab at Duke were performed to define a mouse animal model for studying in vivo CD20 function to test potential targets for anti-CD20 immunotherapy (1). (novusbio.com)
  • CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. (eurekaselect.com)
  • By exploiting the immunocompetent mouse model, we have further revealed that the adaptive immune system is essential for the adaptive resistance to anti-CD20 in advanced B-cell lymphoma, opening up a new avenue to combine anti-CD20 with immunotherapy to overcome the resistance of advanced B-cell lymphoma in the clinic. (aacrjournals.org)
  • They used a murine model of T1D to demonstrate that antigen-specific immunotherapy delivered to the fetus is a very effective approach to preventing T1D. (diabetesjournals.org)
  • CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. (cancer.gov)
  • This suggests that a therapeutic with the ability to simultaneously target both CD19 and CD20 could represent a solution to the drawbacks of current therapies. (cancer.gov)
  • Researchers at the National Cancer Institute (NCI) have developed the current invention which is an expression construct for a CAR that targets both CD19 and CD20. (cancer.gov)
  • The result is a more efficient and simultaneous targeting of both CD19 and CD20 by the same T cell. (cancer.gov)
  • Cellular antigens are proteins or oligosaccharides that mark and identify the cell surface as self or nonself . (tabers.com)
  • Generally, CAR consists of tumor associated antigen (TAA) binding domain, hinge domain, transmembrane domain and signaling domain. (biomedcentral.com)
  • The inhibition of tumor growth by anti-CD20 antibody (Ab) treatment is mediated by Ab- and complement-dependent cytotoxicity in xenograft tumor models. (aacrjournals.org)
  • In addition, anti-CD20 therapy for B-cell lymphoma can result in intrinsic and extrinsic tumor resistance to further Ab treatment. (aacrjournals.org)
  • However, adaptive immune response-related resistance has not been well studied in anti-CD20-mediated tumor control, and adaptive immunity has long been underestimated. (aacrjournals.org)
  • Furthermore, we revealed how the tumor-specific T-cell response was initiated by anti-CD20. (aacrjournals.org)
  • Importantly, macrophages were also necessary for the increase in the tumor-specific CTL response after anti-CD20 treatment, via the production of type I IFN to activate DC function. (aacrjournals.org)
  • The therapeutic function of anti-CD20 depends on tumor-specific CD8 + T-cell responses initiated by anti-CD20 through macrophages and DCs. (aacrjournals.org)
  • However, the role of the adaptive immune system in anti-CD20-mediated tumor regression has been ignored until recently. (aacrjournals.org)
  • This study reveals the essential role of adaptive immunity for anti-CD20-mediated tumor regression and its underlying mechanism. (aacrjournals.org)
  • Through studying the mechanism by which anti-CD20 mediates tumor regression, novel strategies for enhancing the anti-CD20 therapeutic effect can be designed and examined in the clinic. (aacrjournals.org)
  • CARs are genetically engineered to combine antigen- or tumor-specific-binding with T-cell activating domains. (genengnews.com)
  • Authors: Babaer D, Zheng M, Ivy MT, Zent R, Tiriveedhi V Abstract Previous phase I DNA-vaccine based clinical trials using Mammaglobin-A (Mam-A), a human breast tumor associated antigen (TAA), demonstrated that this agent was safe and efficient at treating patients with stage IV breast cancer. (medworm.com)
  • The long-term success of cancer vaccines is limited by the diminished expression of human leukocyte antigen (HLA) class I molecules in the tumor microenvironment. (medworm.com)
  • 2. An antibody as claimed in claim 1, wherein the specificity of either the first antibody or the second antibody is directed against animal or human tumor-associated antigen. (google.com)
  • b The presence of ErbB2-specific control protein scFv(FRP5) (lane 1) and CD20-specific scFv(Leu-16) (lane 2) in periplasmic extracts was confirmed by SDS-PAGE and immunoblot analysis with FLAG-tag specific Mab M2. (springer.com)
  • however, differences in phosphoproteins induced by anti-IgM and anti-CD20 were detected using a fynSH2-fusion protein. (jimmunol.org)
  • A Czech group examined the role of the adaptor protein Lck-interacting molecule (LIME) in CD4 and CD8 signaling through CD20 antibody immunoblotting (4). (novusbio.com)
  • Meng Li, Wei Han, Quiyang Zhang, Xiaochang Xue, Zenglu Wang and Yingqi Zhang, " Development of a Mimotope-Based Vaccine Against CD20 Antigen", Protein & Peptide Letters (2007) 14: 610. (eurekaselect.com)
  • Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression of one protein is retained when the other is lost. (cancer.gov)
  • Description: The 2H7 monoclonal antibody reacts with human CD20, a 33-36 kDa transmembrane protein. (fishersci.com)
  • The protein marker in the Rh group of antigens that stimulates the greatest immune response. (tabers.com)
  • CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. (abcam.com)
  • This antibody recognizes the antigen presenting on the cell surface membrane of tissue macrophages. (osu.edu)
  • Recognizes the human CD20 cell surface antigen, a 33-37kD phosphoprotein. (lsbio.com)
  • a For periplasmic expression of CD20-specific scFv(Leu-16) under control of the IPTGinducible tac promoter, cDNA fragments encoding heavy (VH) and light chain variable domains (VL) of monoclonal antibody Leu-16 were connected by a flexible linker sequence and fused to the ompA signal peptide (SP) in the bacterial expression vector pSW50. (springer.com)
  • Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. (umassmed.edu)
  • Two cDNA clones encoding the pan-B cell CD20 antigen were isolated from a COS cell expression library. (rupress.org)
  • A case of a follicular lymphoma transformed into a CD20+ is described which progressed with the loss of CD20 expression after 8 cycles of R-CHOP. (bvsalud.org)
  • A monoclonal antibody against the extracellular domain of mouse and human epithelial V-like antigen 1 reveals a restricted expression pattern among CD4- CD8- thymocytes. (medworm.com)
  • CHO-Anti-Human CD20 F(ab) stable cell line is clonally-derived from a CHO cell line, which has been transfected with an anti-human CD20 F(ab) gene to allow expression of the F(ab). (creativebiomart.net)
  • Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency. (fishersci.com)
  • Isolation, tissue distribution, and chromosomal localization of a novel testis-specific human four-transmembrane gene related to CD20 and FcepsilonRI-beta. (ebi.ac.uk)
  • The predicted CD20 sequence is 297 residues long and contains three hydrophobic domains, one of which is long enough to span the membrane twice. (rupress.org)
  • Here we demonstrate that anti-CD20 mediated induction of c-myc mRNA is inhibited by the tyrosine kinase inhibitor herbimycin A, that CD20 is associated with both tyrosine and serine kinase activity, and that tyrosine phosphorylation of multiple substrates is induced within minutes upon ligation of CD20 with mAb. (jimmunol.org)
  • Previously, using DNL, we generated a novel immunocytokine named 20-2b-2b, formerly 20-2b, which comprises four IFNα2b groups tethered to the humanized anti-CD20 MAb, veltuzumab (v-mab), and showed potent in vitro cytotoxicity and superior therapeutic efficacy in human NHL xenograft models ( 10 ). (aacrjournals.org)
  • Both phospholipase C-gamma 1 and -gamma 2 were phosphorylated on tyrosine after cross-linking of CD20-bound mAb, and this correlated with increases in intracellular calcium that were partially resistant to depletion of extracellular calcium with EGTA. (jimmunol.org)
  • Studies have demonstrated that CD20-initiated intracellular signals involve tyrosine kinase activation and that CD20 is tightly associated with both serine and tyrosine kinases. (miltenyibiotec.com)
  • The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. (creative-biolabs.com)
  • The tracer targets the antigen CD20, which is expressed extensively in lymph nodes. (eurekalert.org)
  • This drug targets the CD20 antigen, which many types of lymphoma make too much of. (webmd.com)
  • CD20 antibody LS-C13100 is an FITC-conjugated mouse monoclonal antibody to CD20 from human. (lsbio.com)
  • Ease of use and versatility also enable the VECTASTAIN ® ABC kits and ImmPRESS ™ reagents to be incor- porated into applications such as multiple antigen labeling, without requiring significant pro- cedural alterations or additional reagents. (vectorlabs.com)
  • A great amount of non-specific binding causes high background staining which will mask the detection of the target antigen. (wikipedia.org)
  • Real mutated cancer antigens exist. (halfbakery.com)
  • True weird freaky cancer antigens certainly exist in great variety. (halfbakery.com)
  • Cancer antigens are used in clinical medicine to screen body fluids for tumors or to follow the response of tumors to treatment. (tabers.com)
  • All of them hit normal tissue antigens that are either overexpressed on cancer or more important to cancer. (halfbakery.com)
  • Depending on the method of fixation and tissue preservation, the sample may require additional steps to make the epitopes available for antibody binding, including deparaffinization and antigen retrieval. (wikipedia.org)
  • Depending on the tissue type and the method of antigen detection, endogenous biotin or enzymes may need to be blocked or quenched, respectively, prior to antibody staining. (wikipedia.org)
  • Quality control should as a minimum include a tissue known to express the antigen as a positive control and negative controls of tissue known not to express the antigen, as well as the test tissue probed in the same way with omission of the primary antibody (or better, absorption of the primary antibody). (wikipedia.org)
  • Accurate, reliable localization of two or more antigens on the same tissue section is a powerful research tool that can be easily applied in standard laboratory settings. (vectorlabs.com)
  • Vector Laboratories offers many solutions for the localization of two or more antigens in the same tissue section. (vectorlabs.com)
  • In general, immunoenzymatic methods can be used to stain two or more antigens in the same tissue section when the antigens are located in different cell types or different compartments of the same cell. (vectorlabs.com)
  • Matching certain types of tissue antigens is important for the success of an organ transplant. (tabers.com)
  • An antigen that occurs in some individuals of the same species. (tabers.com)
  • Possible explanations for the dual activities of 1F5 and implications for the role of the CD20 antigen in B cell differentiation are discussed. (jimmunol.org)
  • Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. (jimmunol.org)
  • CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation. (fishersci.com)
  • The ready-to-use lentiviral particles of Lenti-CD20 CAR (scFv-28OXζ, 1F5)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. (creative-biolabs.com)
  • We show that 20-C2-2b has potent cytotoxicity against four NHL cell lines as well as eight MM cell lines, seven of which express HLA-DR. Because 20-C2-2b has antibody-dependent cellular cytotoxicity (ADCC), but not CDC, and can target both CD20 and HLA-DR, it may be useful for therapy of a broad range of hematopoietic cancers that express either or both antigens. (aacrjournals.org)
  • upon binding to CD20, obinutuzumab activates complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, resulting in cell death (Sehn 2012). (drugs.com)